Kyle Kuvalanka
Director/Board Member bij IMV INC.
Vermogen: - $ op 31-12-2023
Profiel
Kyle D.
Kuvalanka is an Independent Director at IMV, Inc. and will be the Chief Financial Officer & Chief Business Officer at Rome Therapeutics, Inc. starting in 2023.
He was previously the Vice President-Strategy & Business Development at Millennium Pharmaceuticals, Inc. from 2009 to 2013, the CFO, Treasurer, CAO & Chief Business Officer at Blueprint Medicines Corp.
from 2013 to 2015, and the Chief Operating, Financial & Accounting Officer at Syros Pharmaceuticals, Inc. from 2015 to 2017.
He also held the position of Chief Operating & Financial Officer at Goldfinch Bio, Inc. Mr. Kuvalanka received his undergraduate degree from Wesleyan University and his MBA from The Wharton School of the University of Pennsylvania.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IMV INC.
-.--% | 31-03-2023 | 0 ( -.--% ) | - $ | 31-12-2023 |
Actieve functies van Kyle Kuvalanka
| Bedrijven | Functie | Begin |
|---|---|---|
| IMV INC. | Director/Board Member | 01-04-2021 |
Rome Therapeutics, Inc.
 Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | Director of Finance/CFO | 04-10-2023 |
Eerdere bekende functies van Kyle Kuvalanka
| Bedrijven | Functie | Einde |
|---|---|---|
| SYROS PHARMACEUTICALS, INC. | Director of Finance/CFO | 22-09-2017 |
| BLUEPRINT MEDICINES CORPORATION | Director of Finance/CFO | 18-09-2015 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01-09-2013 |
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA. | Director of Finance/CFO | - |
Opleiding van Kyle Kuvalanka
| Wesleyan University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| IMV INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| SYROS PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Goldfinch Bio, Inc.
Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA. | Health Technology |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | Health Technology |
